Dyne Therapeutics, Inc. Common Stock
DYN
DYN: Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.
moreShow DYN Financials
Recent trades of DYN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by DYN's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy Jun. 20, 2023
-
Patent Title: Anti-transferrin receptor antibody and uses thereof Jun. 13, 2023
-
Patent Title: Anti-transferrin receptor (tfr) antibody and uses thereof May. 16, 2023
-
Patent Title: Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy May. 02, 2023
-
Patent Title: Muscle targeting complexes and uses thereof for treating myotonic dystrophy Apr. 25, 2023
-
Patent Title: Muscle targeting complexes and uses thereof for treating dystrophinopathies Apr. 25, 2023
-
Patent Title: Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy or a disease associated with muscle weakness Apr. 18, 2023
-
Patent Title: Methods of delivering an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy Dec. 06, 2022
-
Patent Title: Muscle targeting complexes and uses thereof for treating dystrophinopathies Nov. 15, 2022
-
Patent Title: Methods of intravenouisly delivering anti-transferrin antibody/oligonucleotide complexes to subjects having muscular dystrophy Jul. 19, 2022
-
Patent Title: Muscle targeting complexes and uses thereof for treating dystrophinopathies Jun. 28, 2022
-
Patent Title: Complex comprising anti-transferrin receptor antibody covalently linked to an oligonucleotide that targets dux4 rna Mar. 29, 2022
-
Patent Title: Muscle targeting complexes and uses thereof for treating dystrophinopathies Feb. 15, 2022
-
Patent Title: Muscle targeting complexes and uses thereof for treating dystrophinopathies Nov. 09, 2021
-
Patent Title: Method of reducing expression of dux4 in a muscle cell by administering an anti-transferrin receptor antibody linked to an oligonucleotide targeting dux4 Sep. 07, 2021
Federal grants, loans, and purchases
Followers on DYN's company Twitter account
Number of mentions of DYN in WallStreetBets Daily Discussion
Recent insights relating to DYN
Recent picks made for DYN stock on CNBC
ETFs with the largest estimated holdings in DYN
Flights by private jets registered to DYN